AAPGAscentage Pharma Group Inc.Finished
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
Chronic Myeloid Leukemia, Chronic Phase
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Aug 2024, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 2
- Patients
- 144 (final count)
- Started
- Oct 21, 2019
- Main results expected
- Aug 1, 2024
- Fully finished
- Aug 1, 2024
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Event free survival (EFS)
Measured over: By the end of Cycle 24 (each cycle is 28 days)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2024-08-01, no fading
Raw record changes
- none yet
Trial ID NCT04126681 · record last updated 2025-03-03 · checked 2026-11-09 15:47 UTC